Latest research on Ezetimibe

Ezetimibe is an anti-hyperlipidemic medication which is used to lower cholesterol levels. Specifically, it appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes.

Latest findings

In a relatively large, multicenter study, involving patients with primary hypercholesterolemia already receiving statin monotherapy (but who had not met their NCEP ATP II target LDL-C goal), patients were randomized to receive either Ezetimibe or placebo in addition to their current statin therapy. [source, 2004]
At the conclusion of this 8 week study, the Ezetimibe and statin groups were found to have a significantly lower total-C, LDL-C, Apo B, and TG, and increased HDL-C when compared to the statin only and placebo groups. [source, 2004]
Furthermore, LDL-C reductions induced by Ezetimibe were generally consistent across all statins groups [30]. [source, 2004]
Another multicenter, double-blind, randomized trial examined the effects of Ezetimibe on patients suffering from (HoFH). [source, 2004]
The addition of Ezetimibe reduced LDL-C by an additional 20.5 % in contrast to only 6.7 % reduction that resulted from doubling the statin dose [31]. [source, 2004]
The addition of Ezetimibe to statins is superior to treatment with statins alone in lowering non-HDL-C, Ezetimibe co-administered with Simvastatin lowered non-HDL-C by 47.1% whereas, Simvastatin monotherapy lowered non-HDL-C by 33.6% when results were pooled across different doses [33]. [source, 2004]
In terms of modifying risk factors other than LDL-C, the co-administration of Ezetimibe with statins had a more favorable effect on HDL-C and TG when compared to statins therapy alone [33]. [source, 2004]
In conclusion, the addition of Ezetimibe to statins produced further lowering of LDL-C of approximately 15–20 % with no apparent increase in side effects. [source, 2004]
Ezetimibe co-administration with fibric acid derivatives was examined in a randomized, evaluator-blind, placebo-controlled, parallel-group study of 32 healthy hypereholesterolemics. [source, 2004]
Ezetimibe co-administration with Fenofibrate was found to produce clinically significant reductions in LDL-C (36.3%) compared to the Fenofibrate group (22.3%) with a more favorable TG and HDL-C profile [34]. [source, 2004]